At present, only PD-L1 expression levels on tumor cells have been widely used as a standard predictor to drive anti-PD-1/PD-L1 treatment in the clinic, while multiple other markers detected by genomic, transcriptomic, proteomic and metabolomic analyses are still being investigated and validated. This evidence concerns the gene PDCD1 and neoplasm.